{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:00:39Z","timestamp":1785859239906,"version":"3.56.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1097\/01.crd.0000201550.94389.50","type":"journal-article","created":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T04:03:37Z","timestamp":1139803417000},"page":"81-87","source":"Crossref","is-referenced-by-count":16,"title":["Suppression of the Renin\u2013Angiotensin\u2013Aldosterone System in Chronic Heart Failure"],"prefix":"10.1097","volume":"14","author":[{"given":"Ulrich P.","family":"Jorde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"60A","DOI":"10.1016\/S0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"62","author":"Swedberg","year":"1988","journal-title":"Am J Cardiol"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group.","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators.","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0021-9258(17)42144-2","article-title":"Regulated cleavage-secretion of the membrane-bound angiotensin-converting enzyme.","volume":"269","author":"Ramchandran","year":"1994","journal-title":"J Biol Chem"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0005-2744(71)90142-2","article-title":"Concentrations of angiotensin-converting enzyme in tissues of the rat.","volume":"250","author":"Cushman","year":"1971","journal-title":"Biochim Biophys Acta"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1161\/01.CIR.98.25.2842","article-title":"Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.","volume":"98","author":"Hornig","year":"1998","journal-title":"Circulation"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002280050216","article-title":"Effect of enalapril and quinapril on forearm vascular ACE in man.","volume":"51","author":"Lyons","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1172\/JCI119419","article-title":"The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.","volume":"99","author":"Esther","year":"1997","journal-title":"J Clin Invest"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0735-1097(99)00537-9","article-title":"Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).","volume":"35","author":"Anderson","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.94.8.1886","article-title":"Evidence for the existence of a functional cardiac renin\u2013angiotensin system in humans.","volume":"94","author":"Neri Serneri","year":"1996","journal-title":"Circulation"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1161\/01.CIR.92.12.3568","article-title":"Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats.","volume":"92","author":"Ruzicka","year":"1995","journal-title":"Circulation"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.amjcard.2004.08.027","article-title":"Comparison of suppression of the circulating and vascular renin\u2013angiotensin system by enalapril versus trandolapril in chronic heart failure.","volume":"94","author":"Jorde","year":"2004","journal-title":"Am J Cardiol"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjp.0704452","article-title":"Vasoconstriction is determined by interstitial rather than circulating angiotensin II.","volume":"135","author":"Schuijt","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.HYP.0000050650.52007.83","article-title":"Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II.","volume":"41","author":"Cole","year":"2003","journal-title":"Hypertension"},{"key":"R21-5-20210203","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1067\/mhj.2003.24","article-title":"Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study.","volume":"145","author":"Borghi","year":"2003","journal-title":"Am Heart J"},{"key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.","volume":"99","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/01.CIR.95.6.1455","article-title":"Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1\u20139) formed by heart carboxypeptidase A-like activity.","volume":"95","author":"Kokkonen","year":"1997","journal-title":"Circulation"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.101.8.844","article-title":"Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.","volume":"101","author":"Jorde","year":"2000","journal-title":"Circulation"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0735-1097(02)01689-3","article-title":"Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.","volume":"39","author":"Farquharson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II.","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(03)14294-8","article-title":"Candesartan and heart failure: the allure of CHARM.","volume":"362","author":"White","year":"2003","journal-title":"Lancet"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.","volume":"2","author":"Struthers","year":"1996","journal-title":"J Card Fail"},{"key":"R39-5-20210203","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R40-5-20210203","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1440-1681.2004.04079.x","article-title":"Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.","volume":"31","author":"Rogerson","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R41-5-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0895-7061(99)00005-9","article-title":"Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin\u2013angiotensin\u2013aldosterone system in normotensive and hypertensive subjects.","volume":"12","author":"Blumenfeld","year":"1999","journal-title":"Am J Hypertens"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2005.01.052","article-title":"Increased carotid atherosclerosis in andropausal middle-aged men.","volume":"45","author":"Makinen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R43-5-20210203","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjcard.2003.07.044","article-title":"Effect of testosterone therapy on QT dispersion in men with heart failure.","volume":"92","author":"Malkin","year":"2003","journal-title":"Am J Cardiol"},{"key":"R44-5-20210203","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"R45-5-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R46-5-20210203","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"key":"R47-5-20210203","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.294.10.1240","article-title":"Risk-treatment mismatch in the pharmacotherapy of heart failure.","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045415-200603000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:08:10Z","timestamp":1785856090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-200603000-00005"}},"subtitle":["Choice of Agents and Clinical Impact"],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000201550.94389.50","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}